Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2024

Open Access 01-12-2024 | Lymphadenectomy | Review

Optimal lymph node dissection for gastric cancer: a narrative review

Authors: Raphaël Nico, Julie Veziant, Amélie Chau, Clarisse Eveno, Guillaume Piessen

Published in: World Journal of Surgical Oncology | Issue 1/2024

Login to get access

Abstract

The management of gastric cancer has long been debated, particularly the extent of lymph node (LN) dissection required during curative surgery. LN invasion stands out as the most critical prognostic factor in gastric cancer. Historically, Japanese academic societies were the pioneers in defining a classification system for regional gastric LN stations, numbering them from 1 to 16. This classification was later used to differentiate between different types of LN dissection, such as D1, D2 and D3. However, these definitions were often considered too complex to be universally adopted, resulting in wide variations in recommendations from one country to another and making it difficult to compare published studies. In addition, the optimal extent of LN dissection remains uncertain, with initially recommended dissections being extensive but associated with significant morbidity without a clear survival benefit. The aim of this review is to make a case for extending LN dissection based on the existing literature, which includes a comprehensive examination of the current definitions of lymphadenectomy and an analysis of the results of all randomised controlled trials evaluating morbidity, mortality and long-term survival associated with different types of LN dissection. Finally, we provide a summary of the various recommendations issued by organizations such as the Japanese Gastric Research Association, the National Comprehensive Cancer Network, the European Society for Medical Oncology, and the French National Thesaurus of Digestive Oncology.
Literature
1.
go back to reference Smyth EC, Fassan M, Cunningham D, Allum WH, Okines AFC, Lampis A, et al. Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy trial. J Clin Oncol off J Am Soc Clin Oncol. 2016;34(23):2721–7.CrossRef Smyth EC, Fassan M, Cunningham D, Allum WH, Okines AFC, Lampis A, et al. Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy trial. J Clin Oncol off J Am Soc Clin Oncol. 2016;34(23):2721–7.CrossRef
2.
go back to reference Amin MB, Edge S, Greene F, et al. Stomach cancer. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017. pp. 203–20. Amin MB, Edge S, Greene F, et al. Stomach cancer. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017. pp. 203–20.
3.
go back to reference Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-Population database. J Clin Oncol. 2005;23(28):7114–24.CrossRefPubMed Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-Population database. J Clin Oncol. 2005;23(28):7114–24.CrossRefPubMed
4.
go back to reference Mariette C, Piessen G, Vons C. La Chirurgie ganglionnaire dans les cancers de l’œsophage et de l’estomac. J Chir (Paris). 2008;145(6):S1221–9.CrossRef Mariette C, Piessen G, Vons C. La Chirurgie ganglionnaire dans les cancers de l’œsophage et de l’estomac. J Chir (Paris). 2008;145(6):S1221–9.CrossRef
5.
go back to reference Zhou Y, Yu F, Wu L, Ye F, Zhang L, Li Y. Survival after gastrectomy in node-negative gastric cancer: a review and meta-analysis of prognostic factors. Med Sci Monit Int Med J Exp Clin Res. 2015;21:1911–9. Zhou Y, Yu F, Wu L, Ye F, Zhang L, Li Y. Survival after gastrectomy in node-negative gastric cancer: a review and meta-analysis of prognostic factors. Med Sci Monit Int Med J Exp Clin Res. 2015;21:1911–9.
6.
go back to reference Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453–62.CrossRefPubMed Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453–62.CrossRefPubMed
7.
go back to reference Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg. 2017;265(2):277–83.CrossRefPubMed Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg. 2017;265(2):277–83.CrossRefPubMed
8.
go back to reference Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340(12):908–14.CrossRefPubMed Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340(12):908–14.CrossRefPubMed
9.
go back to reference Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical co-operative group. Br J Cancer. 1999;79(9–10):1522–30.CrossRefPubMedPubMedCentral Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical co-operative group. Br J Cancer. 1999;79(9–10):1522–30.CrossRefPubMedPubMedCentral
10.
go back to reference Degiuli M, Sasako M, Ponti A, Vendrame A, Tomatis M, Mazza C, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg. 2014;101(2):23–31.PubMed Degiuli M, Sasako M, Ponti A, Vendrame A, Tomatis M, Mazza C, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg. 2014;101(2):23–31.PubMed
11.
go back to reference Degiuli M, Sasako M, Ponti A, Italian gastric cancer study group. Morbidity and mortality in the Italian gastric cancer study group randomized clinical trial of d1 versus D2 resection for gastric cancer. Br J Surg. 2010;97(5):643–9.CrossRefPubMed Degiuli M, Sasako M, Ponti A, Italian gastric cancer study group. Morbidity and mortality in the Italian gastric cancer study group randomized clinical trial of d1 versus D2 resection for gastric cancer. Br J Surg. 2010;97(5):643–9.CrossRefPubMed
12.
go back to reference Degiuli M, Reddavid R, Tomatis M, Ponti A, Morino M, Sasako M et al. D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian gastric cancer study group D1 versus D2 randomised controlled trial. Eur J Cancer Oxf Engl. 1990. 2021;150:10–22. Degiuli M, Reddavid R, Tomatis M, Ponti A, Morino M, Sasako M et al. D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian gastric cancer study group D1 versus D2 randomised controlled trial. Eur J Cancer Oxf Engl. 1990. 2021;150:10–22.
13.
go back to reference Songun I, Putter H, Kranenbarg EMK, Sasako M, van de Velde CJH. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–49.CrossRefPubMed Songun I, Putter H, Kranenbarg EMK, Sasako M, van de Velde CJH. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–49.CrossRefPubMed
14.
go back to reference Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol off J Eur Soc Med Oncol. 2016;27(suppl 5):v38–49.CrossRef Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol off J Eur Soc Med Oncol. 2016;27(suppl 5):v38–49.CrossRef
15.
go back to reference Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg. 1981;11(2):127–39.CrossRefPubMed Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg. 1981;11(2):127–39.CrossRefPubMed
16.
go back to reference Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2011;14(2):113–23. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2011;14(2):113–23.
17.
go back to reference Sano T, Aiko T. New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. Gastric Cancer off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2011;14(2):97–100. Sano T, Aiko T. New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. Gastric Cancer off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2011;14(2):97–100.
18.
go back to reference Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol off J Eur Soc Med Oncol. 2022;33(10):1005–20.CrossRef Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol off J Eur Soc Med Oncol. 2022;33(10):1005–20.CrossRef
19.
go back to reference Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, Version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2022;20(2):167–92.CrossRefPubMed Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, Version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2022;20(2):167–92.CrossRefPubMed
20.
go back to reference Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2023;26(1):1–25. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2023;26(1):1–25.
21.
go back to reference Slim K, Blay JY, Brouquet A, Chatelain D, Comy M, Delpero JR, et al. [Digestive oncology: surgical practices]. J Chir (Paris). 2009;146(Suppl 2):S11–80.PubMed Slim K, Blay JY, Brouquet A, Chatelain D, Comy M, Delpero JR, et al. [Digestive oncology: surgical practices]. J Chir (Paris). 2009;146(Suppl 2):S11–80.PubMed
22.
go back to reference Zaanan A, Barret M, Buecher B, Benhaim L, Chapelle N, Dubreuil O, Ducreux M, Durand-Labrunie J, Fares N, Gagniere J, Granger V, Ernst O, Renaud F, Vendrely V, Michel P. M. Ducreux, O. Bouché. « cancer de l’estomac ». Thésaurus national de cancérologie Digestive, octobre 2022, en ligne [http://www.tncd.org] Zaanan A, Barret M, Buecher B, Benhaim L, Chapelle N, Dubreuil O, Ducreux M, Durand-Labrunie J, Fares N, Gagniere J, Granger V, Ernst O, Renaud F, Vendrely V, Michel P. M. Ducreux, O. Bouché. « cancer de l’estomac ». Thésaurus national de cancérologie Digestive, octobre 2022, en ligne [http://​www.​tncd.​org]
23.
go back to reference Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg. 1988;75(2):110–2.CrossRefPubMed Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg. 1988;75(2):110–2.CrossRefPubMed
24.
go back to reference Robertson CS, Chung SC, Woods SD, Griffin SM, Raimes SA, Lau JT, et al. A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg. 1994;220(2):176–82.CrossRefPubMedPubMedCentral Robertson CS, Chung SC, Woods SD, Griffin SM, Raimes SA, Lau JT, et al. A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg. 1994;220(2):176–82.CrossRefPubMedPubMedCentral
25.
go back to reference Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet Lond Engl. 1995;345(8952):745–8.CrossRef Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet Lond Engl. 1995;345(8952):745–8.CrossRef
26.
go back to reference Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The surgical cooperative group. Lancet Lond Engl. 1996;347(9007):995–9.CrossRef Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The surgical cooperative group. Lancet Lond Engl. 1996;347(9007):995–9.CrossRef
27.
go back to reference Galizia G, Lieto E, De Vita F, Castellano P, Ferraraccio F, Zamboli A, et al. Modified versus standard D2 lymphadenectomy in total gastrectomy for nonjunctional gastric carcinoma with lymph node metastasis. Surgery. 2015;157(2):285–96.CrossRefPubMed Galizia G, Lieto E, De Vita F, Castellano P, Ferraraccio F, Zamboli A, et al. Modified versus standard D2 lymphadenectomy in total gastrectomy for nonjunctional gastric carcinoma with lymph node metastasis. Surgery. 2015;157(2):285–96.CrossRefPubMed
28.
go back to reference Wu CW, Hsiung CA, Lo SS, Hsieh MC, Shia LT, Whang-Peng J. Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br J Surg. 2004;91(3):283–7.CrossRefPubMed Wu CW, Hsiung CA, Lo SS, Hsieh MC, Shia LT, Whang-Peng J. Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br J Surg. 2004;91(3):283–7.CrossRefPubMed
29.
go back to reference Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AFY, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006;7(4):309–15.CrossRefPubMed Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AFY, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006;7(4):309–15.CrossRefPubMed
30.
go back to reference Yu P, Du Y, Xu Z, Huang L, Cheng X. Comparison of D2 and D2 plus radical surgery for advanced distal gastric cancer: a randomized controlled study. World J Surg Oncol. 2019;17(1):28.CrossRefPubMedPubMedCentral Yu P, Du Y, Xu Z, Huang L, Cheng X. Comparison of D2 and D2 plus radical surgery for advanced distal gastric cancer: a randomized controlled study. World J Surg Oncol. 2019;17(1):28.CrossRefPubMedPubMedCentral
31.
go back to reference Kulig J, Popiela T, Kolodziejczyk P, Sierzega M, Szczepanik A, Polish Gastric Cancer Study Group. Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: an interim safety analysis of a multicenter, randomized, clinical trial. Am J Surg. 2007;193(1):10–5.CrossRefPubMed Kulig J, Popiela T, Kolodziejczyk P, Sierzega M, Szczepanik A, Polish Gastric Cancer Study Group. Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: an interim safety analysis of a multicenter, randomized, clinical trial. Am J Surg. 2007;193(1):10–5.CrossRefPubMed
32.
go back to reference Yonemura Y, Wu CC, Fukushima N, Honda I, Bandou E, Kawamura T, et al. Operative morbidity and mortality after D2 and D4 extended dissection for advanced gastric cancer: a prospective randomized trial conducted by Asian surgeons. Hepatogastroenterology. 2006;53(69):389–94.PubMed Yonemura Y, Wu CC, Fukushima N, Honda I, Bandou E, Kawamura T, et al. Operative morbidity and mortality after D2 and D4 extended dissection for advanced gastric cancer: a prospective randomized trial conducted by Asian surgeons. Hepatogastroenterology. 2006;53(69):389–94.PubMed
33.
go back to reference Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy–Japan clinical oncology group study 9501. J Clin Oncol off J Am Soc Clin Oncol. 2004;22(14):2767–73.CrossRef Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy–Japan clinical oncology group study 9501. J Clin Oncol off J Am Soc Clin Oncol. 2004;22(14):2767–73.CrossRef
34.
go back to reference Maeta M, Yamashiro H, Saito H, Katano K, Kondo A, Tsujitani S, et al. A prospective pilot study of extended (D3) and superextended para-aortic lymphadenectomy (D4) in patients with T3 or T4 gastric cancer managed by total gastrectomy. Surgery. 1999;125(3):325–31.CrossRefPubMed Maeta M, Yamashiro H, Saito H, Katano K, Kondo A, Tsujitani S, et al. A prospective pilot study of extended (D3) and superextended para-aortic lymphadenectomy (D4) in patients with T3 or T4 gastric cancer managed by total gastrectomy. Surgery. 1999;125(3):325–31.CrossRefPubMed
35.
go back to reference Csendes A, Burdiles P, Rojas J, Braghetto I, Diaz JC, Maluenda F. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery. 2002;131(4):401–7.CrossRefPubMed Csendes A, Burdiles P, Rojas J, Braghetto I, Diaz JC, Maluenda F. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery. 2002;131(4):401–7.CrossRefPubMed
36.
go back to reference Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg. 2006;93(5):559–63.CrossRefPubMed Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg. 2006;93(5):559–63.CrossRefPubMed
37.
go back to reference Mocellin S, McCulloch P, Kazi H, Gama-Rodrigues JJ, Yuan Y, Nitti D. Extent of lymph node dissection for adenocarcinoma of the stomach. Cochrane Database Syst Rev. 2015;2015(8):CD001964.PubMedPubMedCentral Mocellin S, McCulloch P, Kazi H, Gama-Rodrigues JJ, Yuan Y, Nitti D. Extent of lymph node dissection for adenocarcinoma of the stomach. Cochrane Database Syst Rev. 2015;2015(8):CD001964.PubMedPubMedCentral
38.
go back to reference Faiz Z, Hayashi T, Yoshikawa T. Lymph node dissection for gastric cancer: establishment of D2 and the current position of splenectomy in Europe and Japan. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2021;47(9):2233–6. Faiz Z, Hayashi T, Yoshikawa T. Lymph node dissection for gastric cancer: establishment of D2 and the current position of splenectomy in Europe and Japan. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2021;47(9):2233–6.
39.
go back to reference Huang ZN, Tang YH, Zhong Q, Li P, Xie JW, Wang JB et al. Assessment of laparoscopic indocyanine green tracer-guided lymphadenectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a randomized controlled trial. Ann Surg. 2024. Huang ZN, Tang YH, Zhong Q, Li P, Xie JW, Wang JB et al. Assessment of laparoscopic indocyanine green tracer-guided lymphadenectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a randomized controlled trial. Ann Surg. 2024.
40.
go back to reference Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol. 2017;3(9):1237–44.CrossRefPubMedPubMedCentral Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol. 2017;3(9):1237–44.CrossRefPubMedPubMedCentral
41.
go back to reference Al-Batran SE, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, et al. The renaissance (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer. 2017;17(1):893.CrossRefPubMedPubMedCentral Al-Batran SE, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, et al. The renaissance (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer. 2017;17(1):893.CrossRefPubMedPubMedCentral
42.
go back to reference University Hospital. Lille. Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer - a Multicenter, Prospective, Open-labeled, Two-armed, Randomized, Controlled Phase III Trial. clinicaltrials.gov; 2022 Mar [cited 2024 Jan 1]. Report No.: NCT03042169. https://clinicaltrials.gov/study/NCT03042169 University Hospital. Lille. Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer - a Multicenter, Prospective, Open-labeled, Two-armed, Randomized, Controlled Phase III Trial. clinicaltrials.gov; 2022 Mar [cited 2024 Jan 1]. Report No.: NCT03042169. https://​clinicaltrials.​gov/​study/​NCT03042169
Metadata
Title
Optimal lymph node dissection for gastric cancer: a narrative review
Authors
Raphaël Nico
Julie Veziant
Amélie Chau
Clarisse Eveno
Guillaume Piessen
Publication date
01-12-2024
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2024
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-024-03388-4

Other articles of this Issue 1/2024

World Journal of Surgical Oncology 1/2024 Go to the issue